RxDoctor Payments Data

Kevin Koehler, MD

Family Medicine · Tupelo, MSNPI 1710955984

Payments from drug & device makers

$1,023in general payments, 2019–2025

Across 55 payments — averaging $18.60 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$301
  • Otsuka America Pharmaceutical, Inc.$140
  • Genentech USA, Inc.$97
  • AbbVie$90
  • Takeda Pharmaceuticals U.S.A., Inc.$70
  • Pfizer$59
  • plus $266 from 9 others

What the payments were for

  • Food & beverage$1,023100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$1,023 in reported general payments places this provider in the 60th percentile of 971 family medicine providers in Mississippi.

See all family medicine providers in Mississippi

Medicare billing

Part B allowed, 2024
$4,929
Medicare patients
186
Services billed
502

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide135$179,014
JardianceEmpagliflozin126$155,530
FarxigaDapagliflozin Propanediol54$73,508
EliquisApixaban63$51,427
MounjaroTirzepatide33$34,847
TrulicityDulaglutide21$27,028
WegovySemaglutide14$21,235
TradjentaLinagliptin15$19,705
LinzessLinaclotide22$17,380
Breo ElliptaFluticasone/Vilanterol18$14,644
Trelegy ElliptaFluticasone/Umeclidin/Vilanter13$8,522
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr11$7,382
Novolog FlexpenInsulin Aspart29$6,427
Levemir FlexpenInsulin Detemir25$6,040
Lantus SolostarInsulin Glargine,hum.Rec.Anlog56$5,988

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic, Wegovy$27$200,249149 claims
Boehringer IngelheimJardiance, Tradjenta$32$175,235141 claims
AstraZenecaFarxiga$48$73,50854 claims
PfizerEliquis$59$51,42763 claims
AbbVieLinzess, Synthroid$90$18,60335 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 60th percentile of 971 family medicine providers in Mississippi.

Other family medicine in Tupelo

See the full list for Mississippi

Where these figures come from

Is this you, or does something look wrong? →